<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="EN" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="pmc-domain-id">82</journal-id><journal-id journal-id-type="pmc-domain">aac</journal-id><journal-id journal-id-type="publisher-id">ANTIMICROB AGENTS CHEMOTHER</journal-id><journal-title-group><journal-title>Antimicrobial Agents and Chemotherapy</journal-title></journal-title-group><issn pub-type="ppub">0066-4804</issn><issn pub-type="epub">1098-6596</issn><publisher><publisher-name>American Society for Microbiology (ASM)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC89802</article-id><article-id pub-id-type="pmcid-ver">PMC89802.1</article-id><article-id pub-id-type="pmcaid">89802</article-id><article-id pub-id-type="pmcaiid">89802</article-id><article-id pub-id-type="pmid">10722501</article-id><article-id pub-id-type="doi">10.1128/aac.44.4.985-990.2000</article-id><article-id pub-id-type="publisher-id">0373</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject></subj-group></article-categories><title-group><article-title>Single-Dose Intrapulmonary Pharmacokinetics of  Rifapentine in Normal Subjects</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Conte</surname><given-names initials="JE">John E.</given-names><suffix>Jr.</suffix></name><xref ref-type="aff" rid="N0x9740800.0x95d7aa8">1</xref><xref ref-type="aff" rid="N0x9740800.0x95d7aa8">2</xref><xref ref-type="aff" rid="N0x9740800.0x95d7aa8">3</xref><xref ref-type="author-notes" rid="FN150">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Golden</surname><given-names initials="JA">Jeffrey A.</given-names></name><xref ref-type="aff" rid="N0x9740800.0x95d7aa8">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>McQuitty</surname><given-names initials="M">Mari</given-names></name><xref ref-type="aff" rid="N0x9740800.0x95d7aa8">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kipps</surname><given-names initials="J">Juliana</given-names></name><xref ref-type="aff" rid="N0x9740800.0x95d7aa8">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lin</surname><given-names initials="ET">Emil T.</given-names></name><xref ref-type="aff" rid="N0x9740800.0x95d7aa8">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zurlinden</surname><given-names initials="E">Elisabeth</given-names></name><xref ref-type="aff" rid="N0x9740800.0x95d7aa8">1</xref></contrib></contrib-group><aff id="N0x9740800.0x95d7aa8"> Infectious Diseases Research Laboratory, Department of Epidemiology &amp; Biostatistics,<sup>1</sup> and  Departments of Medicine,<sup>2</sup> Microbiology &amp; Immunology,<sup>3</sup> and  Biopharmaceutical Sciences,<sup>4</sup> University of California, San Francisco, San Francisco, California 94117</aff><author-notes><fn id="FN150"><label>*</label><p>Corresponding author. Mailing address: University of California, San Francisco, 350 Parnassus Ave., Suite 210, San Francisco, CA 94117. Phone: (415) 476-1312. Fax: (415) 476-6612. E-mail: <email>eveb@emailhis.ucsf.edu</email>.</p></fn></author-notes><pub-date pub-type="ppub"><month>4</month><year>2000</year></pub-date><volume>44</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">2483</issue-id><fpage>985</fpage><lpage>990</lpage><history><date date-type="received"><day>12</day><month>5</month><year>1999</year></date><date date-type="rev-request"><day>18</day><month>9</month><year>1999</year></date><date date-type="accepted"><day>10</day><month>1</month><year>2000</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>04</month><year>2000</year></date></event><event event-type="pmc-live"><date><day>12</day><month>09</month><year>2002</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2019-10-31 10:56:17.363"><day>31</day><month>10</month><year>2019</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2000, American Society for Microbiology</copyright-statement><copyright-year>2000</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ac000985.pdf"/><abstract><p>The intrapulmonary pharmacokinetics of rifapentine were studied in 30 volunteers who received a single, oral dose of rifapentine (600 mg). Subgroups of five subjects each underwent bronchoscopy and bronchoalveolar lavage (BAL) at timed intervals following drug administration. Drug concentrations, including the concentration of the primary metabolite 25-desacetyl rifapentine, were determined in plasma, BAL fluid, and alveolar cells (AC) by high-pressure liquid chromatography. The concentrations in epithelial lining fluid (ELF) were calculated by the urea diffusion method. The concentration-time data were fit to two-compartment (plasma) or one-compartment (AC and ELF) models. The peak concentrations in plasma, ELF, and AC, 26.2, 3.7, and 5.3 &#956;g/ml, respectively, occurred at 5, 5, and 7 h after drug administration, respectively. The half-lives and areas under the curve for plasma, ELF, and AC were 18.3 h and 520 &#956;g &#183; h/ml, 20.8 h and 111 &#956;g &#183; h/ml, and 13.0 h and 133 &#956;g &#183; h/ml, respectively. Although the intrapulmonary rifapentine concentrations were less than the plasma rifapentine concentrations at all time periods, they remained above the proposed breakpoint for <italic>M. tuberculosis</italic> (0.5 &#956;g/ml) for the 48-h observation period. These data provide a pharmacokinetic rationale for extended-interval dosing. The optimum dosing regimen for rifapentine will have to be determined by controlled clinical trials.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>